Dear Sir/Madam,

Thank you for sending me the appraisal consultation document.

I am pleased to note that the committee proposes to recommend the use of enzalutamide for the treatment of metastatic hormone relapsed prostate cancer previously treated with a docetaxel-containing regimen. The document clearly indicates that the Committee has taken account of the clinical evidence of the efficacy of the drug and its cost effectiveness.

I hope that this decision is confirmed at the Committee meeting on 20th November 2013 and that the Final Appraisal Document will be published as soon as possible.

Yours faithfully,

[redacted] (Lay witness nominated by Prostate Cancer UK)